Current Use of Aspirin and Antithrombotic Agents in the United States Among Outpatients With Atherothrombotic Disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry)

Baseline prevalence of aspirin and other antithrombotic agent use among US patients enrolled in the REACH Registry.

Baseline prevalence of aspirin and other antithrombotic agent use among US patients enrolled in the REACH Registry who were symptomatic or asymptomatic (with ≥3 risk factors only).

Aspirin use by concomitant antithrombotic medication subgroup in the entire US REACH population and doses used among aspirin users. Bar graph depicts use or lack of aspirin use in the overall population according to concomitant use of other antiplatelet agents and/or oral anticoagulants. Pie charts show dosage breakdown among aspirin users only, accounting for missing data points.

Baseline predictors of (A) lack of aspirin use, (B) low-dose (75 to 100 mg/day; <75 mg was omitted from analysis and >100 mg was used as referent) aspirin use, and (C) lack of antithrombotic use with 95% confidence intervals. *Included thienopyridines (clopidogrel and ticlopidine) and dipyridamole, but not nonsteroidal anti-inflammatory drugs or cilostazol. ^†Included glucosidase inhibitors and meglitinides. ^‡Included fibrates, bioacid resins, niacin, and ezetimibe. ^§For every 10 additional years of age. ^¶History of intermittent claudication associated with lower limb artery angioplasty/stenting/bypass graft. ^∥For every 1 additional year in clinical practice. ABI = ankle-brachial index; ACE-I = angiotensin-converting enzyme inhibitor; A fib = atrial fibrillation; ARB = angiotensin II receptor blocker; CABG = coronary artery bypass graft; CHF = congestive heart failure; DM = diabetes mellitus; MI = myocardial infarction; NSAIDs = nonsteroidal anti-inflammatory drugs; TIA = transient ischemic attack.